June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
The functional impact of CRISPR-Cas9-mediated ZEB1 deficiency in human corneal endothelial cells
Author Affiliations & Notes
  • Yue Li
    The Jules Stein Eye Institute, Monterey Park, California, United States
  • Ricardo F Frausto
    The Jules Stein Eye Institute, Monterey Park, California, United States
  • Doug D Chung
    The Jules Stein Eye Institute, Monterey Park, California, United States
  • E. Maryam Maryam Hanser
    The Jules Stein Eye Institute, Monterey Park, California, United States
  • Austin Kassels
    The Jules Stein Eye Institute, Monterey Park, California, United States
  • Marina Zakharevich
    The Jules Stein Eye Institute, Monterey Park, California, United States
  • Anthony J Aldave
    The Jules Stein Eye Institute, Monterey Park, California, United States
  • Footnotes
    Commercial Relationships   Yue Li, None; Ricardo Frausto, None; Doug Chung, None; E. Maryam Hanser, None; Austin Kassels, None; Marina Zakharevich, None; Anthony Aldave, None
  • Footnotes
    Support  National Eye Institute Grants 1R01 EY022082 (A.J.A.), P30 EY000331 (core grant), the Walton Li Chair in Cornea and Uveitis (A.J.A.), the Stotter Revocable Trust and an unrestricted grant to Stein Eye Institute from Research to Prevent Blindness.
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 5652. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Yue Li, Ricardo F Frausto, Doug D Chung, E. Maryam Maryam Hanser, Austin Kassels, Marina Zakharevich, Anthony J Aldave; The functional impact of CRISPR-Cas9-mediated ZEB1 deficiency in human corneal endothelial cells. Invest. Ophthalmol. Vis. Sci. 2017;58(8):5652.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the impact of ZEB1 deficiency on corneal endothelial cell (CEnC) proliferation, migration and barrier function in a CEnC culture model of posterior polymorphous corneal dystrophy 3 (PPCD3).

Methods : ZEB1+/+, ZEB1+/- and ZEB1-/- HCEnC-21T cell lines, generated using CRISPR-Cas9, were used to test the functional impact of ZEB1 deficiency on various cellular processes (cell proliferation, cell migration and cell barrier). To measure cell proliferation, each HCEnC-21T line was seeded at 10% confluency. The number of cells (N) was counted at 3 hours (defined as N0) and compared to the number of cells at various time points (Nt: 24, 48, 72 and 96 hours) post-seeding and graphed as a ratio (Nt/N0). A non-wounding (electric fence) protocol using a single electrode array was used to evaluate cell migration by electric cell-substrate impedance sensing (ECIS). Cell barrier function was measured using a 40-electrode array designed, in part, for measuring the resistance to an applied electrical field through intercellular junctions.

Results : ZEB1+/- and ZEB1-/- HCEnC-21T cells demonstrated significantly impaired cell proliferation at 72 and 96 hours post-seeding compared with ZEB1+/+ HCEnC-21T cells (p<0.0001). No statistically significant difference in cell proliferation was observed between ZEB1+/- and ZEB1-/- at any of the time points tested. Cell migration assays demonstrated significantly slower migration for ZEB1+/- and ZEB1-/- compared with ZEB1+/+ (p<0.05). The ZEB1-/- cells demonstrated significantly greater cell barrier function compared with both ZEB1+/- and ZEB1+/+ beginning at approximately 60 hours post-seeding. By 120 hours, ZEB1+/- established a significantly increased cell barrier function compared with ZEB1+/+, but significantly reduced compared with ZEB1-/-.

Conclusions : We have established a cell-based model of PPCD3 using CRISPR-Cas9. Herein, we provide the first experimental evidence that human corneal endothelial cells deficient in ZEB1 manifest altered cellular proliferation, migration and barrier function. However, additional investigation is necessary to clarify the relevance of these alterations to the development of PPCD3.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×